Lipoprotein (a) and risk of cardiovascular disease - A systematic review and meta analysis of prospective studies

Clinical Laboratory

Volumn 57, Issue 3-4, 2011, Pages 143-156

  Genser, Bernd ^a,b   Dias, Karen C ^b   Siekmeier, Ruediger ^c   Stojakovic, Tatjana ^d   Grammer, Tanja ^a   Maerz, Winfried ^a,e  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b BGStats Consulting   (Austria)

^c Bundesinstitut fur Arzneimittel und Medizinproducte   (Germany)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e SYNLAB ACADEMY   (Germany)

Author keywords

Cardiovascular disease; Lipoprotein (a); Lp(a); Meta analysis; Systematic review

Indexed keywords

LIPOPROTEIN A;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; COCHRANE LIBRARY; EMBASE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MEDLINE; META ANALYSIS; MORTALITY; PROGNOSIS; PROTEIN LOCALIZATION; RANDOM SAMPLE; REVIEW; STROKE; SYSTEMATIC REVIEW; ARTICLE; BLOOD; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RISK FACTOR; UNITED STATES;

CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEIN(A); PROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 79957842584     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Kostner KM, Kostner GM. Lipoprotein(a): still an enigma? Curr Opin Lipidol 2002 Aug;13(4):391-6.
2. Ariyo AA, Thach C, Tracy R. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 2003 Nov 27; 349(22):2108-15. (Pubitemid 37464535)
3. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 1996 Aug 21;276(7):544-8.
4. Budde T, Fechtrup C, Bosenberg E, et al. Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb 1994 Nov; 14(11):1730-6.
5. Cantin B, Despres JP, Lamarche B, et al. Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study). Am J Cardiol 2002 Mar 15;89(6):662-6. (Pubitemid 34230560)
6. Christopher R, Kailasanatha KM, Nagaraja D, Tripathi M. Casecontrol study of serum lipoprotein(a) and apolipoproteins A-I and B in stroke in the young. Acta Neurol Scand 1996 Aug; 94(2):127-30. (Pubitemid 26308799)
7. Cobbaert C, Jukema JW, Zwinderman AH, Withagen AJ, Lindemans J, Bruschke AV. Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middleaged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. Regression Growth Evaluation Statin Study (REGRESS) Study Group. J Am Coll Cardiol 1997 Nov 15;30(6):1491-9. (Pubitemid 27486467)
8. Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998 Nov; 44(11):2301-6. (Pubitemid 28511752)
9. Cremer P, Nagel D, Labrot B, et al. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 1994 Jul;24(7):444-53.
10. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000 Sep 5;102(10):1082-5.
11. Enas EA, Chacko V, Senthilkumar A, Puthumana N, Mohan V. Elevated lipoprotein(a) - a genetic risk factor for premature vascular disease in people with and without standard risk factors: a review. Dis Mon 2006 Jan;52(1):5-50.
12. Evans RW, Shpilberg O, Shaten BJ, Ali S, Kamboh MI, Kuller LH. Prospective association of lipoprotein(a) concentrations and apo(a) size with coronary heart disease among men in the Multiple Risk Factor Intervention Trial. J Clin Epidemiol 2001 Jan; 54(1):51-7. (Pubitemid 32109230)
13. Fan J, Sun H, Unoki H, Shiomi M, Watanabe T. Enhanced atherosclerosis in Lp(a) WHHL transgenic rabbits. Ann N Y Acad Sci 2001 Dec;947:362-5. (Pubitemid 34059936)
14. Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation 2004 Jun 15;109(23 Suppl 1):IIII5-9.
15. Gaw A, Murray HM, Brown EA. Plasma lipoprotein(a) [Lp(a)] concentrations and cardiovascular events in the elderly: evidence from the prospective study of pravastatin in the elderly at risk (PROSPER). Atherosclerosis 2005 Jun;180(2):381-8.
16. Gazzaruso C, Bruno R, Pujia A, et al. Lipoprotein(a), apolipoprotein(a) polymorphism and coronary atherosclerosis severity in type 2 diabetic patients. Int J Cardiol 2006 Apr 14;108(3): 354-8. (Pubitemid 43339802)
17. Glader CA, Birgander LS, Stenlund H, Dahlen GH. Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden. J Intern Med 2002 Jul;252(1):27-35. (Pubitemid 34743907)
18. Hartmann M, von Birgelen C, Mintz GS, et al. Relation between lipoprotein(a) and fibrinogen and serial intravascular ultrasound plaque progression in left main coronary arteries. J Am Coll Cardiol 2006 Aug 1;48(3):446-52. (Pubitemid 44093948)
19. Hernandez C, Francisco G, Chacon P, Simo R. Lipoprotein(a) as a risk factor for cardiovascular mortality in type 2 diabetic patients: a 10-year follow-up study. Diabetes Care 2005 Apr;28(4): 931-3. (Pubitemid 40434500)
20. Holmer SR, Hengstenberg C, Kraft HG, et al. Association of polymorphisms of the apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction. Circulation 2003 Feb 11; 107(5):696-701. (Pubitemid 36222596)
21. Ichikawa T, Unoki H, Sun H, et al. Lipoprotein(a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo(a) transgenic rabbits. Am J Pathol 2002 Jan; 160(1):227-36. (Pubitemid 34052283)
22. Kronenberg F, Kronenberg MF, Kiechl S, et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 1999 Sep 14;100(11):1154-60. (Pubitemid 29426589)
23. Lippi G, Guidi G. Lipoprotein(a): an emerging cardiovascular risk factor. Crit Rev Clin Lab Sci 2003 Feb;40(1):1-42. (Pubitemid 36250229)
24. Luc G, Bard JM, Arveiler D, et al. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis 2002 Aug; 163(2):377-84. (Pubitemid 34615830)
25. Milionis HJ, Filippatos TD, Loukas T, Bairaktari ET, Tselepis AD, Elisaf MS. Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals. Atherosclerosis 2006 Jul; 187(1):170-6. (Pubitemid 43817011)
26. Shintani S, Kikuchi S, Hamaguchi H, Shiigai T. High serum lipoprotein(a) levels are an independent risk factor for cerebral infarction. Stroke 1993 Jul;24(7):965-9. (Pubitemid 23201451)
27. Sun H, Unoki H, Wang X, et al. Lipoprotein(a) enhances advanced atherosclerosis and vascular calcification in WHHL transgenic rabbits expressing human apolipoprotein(a). J Biol Chem 2002 Dec 6;277(49):47486-92. (Pubitemid 36159266)
28. Terres W, Tatsis E, Pfalzer B, Beil FU, Beisiegel U, Hamm CW. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation 1995 Feb 15; 91(4):948-50.
29. von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001 Feb; 37(2):434-9.
30. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol 1997 Feb;17(2):239-45. (Pubitemid 27098179)
31. Zorio E, Falco C, Arnau MA, et al. Lipoprotein (a) in young individuals as a marker of the presence of ischemic heart disease and the severity of coronary lesions. Haematologica 2006 Apr; 91(4):562-5.
32. Kostner KM, Kostner GM. Therapy of hyper-Lp(a). Handb Exp Pharmacol 2005(170):519-36.
33. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993 Nov 10;270(18):2195-9. (Pubitemid 23323634)
34. Smolders B, Lemmens R, Thijs V. Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke 2007 Jun;38(6): 1959-66. (Pubitemid 46847277)
35. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009 Jul 22;302(4):412-23.
36. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998 May 13;279(18):1477-82. (Pubitemid 28228207)
37. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997 Sep 13;315(7109):629-34.
38. Sterne JA, Egger M. Funnel plots for detecting bias in metaanalysis: guidelines on choice of axis. J Clin Epidemiol 2001 Oct;54(10):1046-55.
39. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 Sep;7(3):177-88.
40. Abu-Lebdeh HS, Hodge DO, Nguyen TT. Predictors of macrovascular disease in patients with type 2 diabetes mellitus. Mayo Clin Proc 2001 Jul;76(7):707-12.
41. Agewall S, Fagerberg B. Lipoprotein(a) was an independent predictor for major coronary events in treated hypertensive men. Clin Cardiol 2002 Jun;25(6):287-90.
42. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994 Mar; 106(1):9-19.
43. Ariyo A, Hennekens CH, Stampfer MJ, Ridker PM. Lipoprotein (a), lipids, aspirin, and risk of myocardial infarction in the Physician's Health Study. J Cardiovasc Risk 1998 Aug;5(4):273-8.
44. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996 Jun 1;77(14):1179-84.
45. Bennet A, Di Angelantonio E, Erqou S, et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med 2008 Mar 24;168(6):598-608.
46. Berg K, Dahlen G, Christophersen B, Cook T, Kjekshus J, Pedersen T. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet 1997 Nov;52(5):254-61.
47. Bostom AG, Gagnon DR, Cupples LA, et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation 1994 Oct;90(4):1688-95.
48. Cantin B, Gagnon F, Moorjani S, et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 1998 Mar 1;31(3): 519-25.
49. Cantin B, Lamarche B, Despres JP, Dagenais GR. Does correction of the friedewald formula using lipoprotein(a) change our estimation of ischemic heart disease risk? The Quebec Cardiovascular Study. Atherosclerosis 2002 Aug;163(2):261-7.
50. Coleman MP, Key TJ, Wang DY, et al. A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women. Atherosclerosis 1992 Feb;92(2-3):177-85.
51. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992 Aug; 86(2):475-82.
52. Dahlen G. Lipoprotein (a) as a risk factor for atherosclerotic diseases. Arctic Med Res 1988;47 Suppl 1:458-61.
53. Dahlen GH, Weinehall L, Stenlund H, et al. Lipoprotein(a) and cholesterol levels act synergistically and apolipoprotein A-I is protective for the incidence of primary acute myocardial infarction in middle-aged males. An incident case-control study from Sweden. J Intern Med 1998 Nov;244(5):425-30.
54. D'Angelo A, Ruotolo G, Garancini P, Sampietro F, Mazzola G, Calori G. Lipoprotein(a), fibrinogen and vascular mortality in an elderly northern Italian population. Haematologica 2006 Dec; 91(12):1613-20.
55. Glader CA, Stegmayr B, Boman J, et al. Chlamydia pneumoniae antibodies and high lipoprotein(a) levels do not predict ischemic cerebral infarctions. Results from a nested case-control study in Northern Sweden. Stroke 1999 Oct;30(10):2013-8.
56. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987 Jul 4;2(8549):3-9.
57. Holmes DT, Schick BA, Humphries KH, Frohlich J. Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem 2005 Nov;51(11):2067-73.
58. Igarashi Y, Aizawa Y, Satoh T, Konno T, Ojima K, Aizawa Y. Predictors of adverse long-term outcome in acute myocardial infarction patients undergoing primary percutaneous transluminal coronary angioplasty: with special reference to the admission concentration of lipoprotein (a). Circ J 2003 Jul;67(7):605-11.
59. Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004 Dec;256(6):482-90.
60. Jauhiainen M, Koskinen P, Ehnholm C, et al. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991 Jul; 89(1):59-67.
61. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 2008 Jan 15;117(2):176-84.
62. Kiechl S, Willeit J, Mayr M, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 2007 Aug;27(8): 1788-95.
63. Klausen IC, Sjol A, Hansen PS, et al. Apolipoprotein(a) isoforms and coronary heart disease in men: a nested case-control study. Atherosclerosis 1997 Jul 11;132(1):77-84.
64. Longenecker JC, Klag MJ, Marcovina SM, et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol 2005 Jun;16(6):1794-802.
65. Lundstam U, Herlitz J, Karlsson T, Linden T, Wiklund O. Serum lipids, lipoprotein(a) level, and apolipoprotein(a) isoforms as prognostic markers in patients with coronary heart disease. J Intern Med 2002 Feb;251(2):111-8.
66. Nguyen TT, Ellefson RD, Hodge DO, Bailey KR, Kottke TE, Abu-Lebdeh HS. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation 1997 Sep 2;96(5):1390-7.
67. Ohira T, Schreiner PJ, Morrisett JD, Chambless LE, Rosamond WD, Folsom AR. Lipoprotein(a) and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2006 Jun;37(6):1407-12.
68. Ridker PM, Stampfer MJ, Hennekens CH. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 1995 Apr 26;273(16):1269-73.
69. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein (a) and coronary heart disease: a prospective casecontrol study in a general population sample of middle aged men. BMJ 1990 Dec 1;301(6763):1248-51.
70. Saely CH, Koch L, Schmid F, et al. Lipoprotein(a), type 2 diabetes and vascular risk in coronary patients. Eur J Clin Invest 2006 Feb;36(2):91-7.
71. Salomaa V, Rasi V, Kulathinal S, et al. Hemostatic factors as predictors of coronary events and total mortality: The FINRISK '92 Hemostasis Study. Arterioscler Thromb Vasc Biol 2002 Feb 1;22(2):353-8.
72. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994 Apr 6;271(13):999-1003.
73. Seed M, Ayres KL, Humphries SE, Miller GJ. Lipoprotein (a) as a predictor of myocardial infarction in middle-aged men. Am J Med 2001 Jan;110(1):22-7.
74. Shai I, Schulze MB, Manson JE, Stampfer MJ, Rifai N, Hu FB. A prospective study of lipoprotein(a) and risk of coronary heart disease among women with type 2 diabetes. Diabetologia 2005 Aug;48(8):1469-76.
75. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000 Apr 12;283(14): 1845-52.
76. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 1992 May 15;69(16):1251-4.
77. Simons LA, Simons J, Friedlander Y, McCallum J. Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years. Atherosclerosis 2001 Nov;159(1):201-8.
78. Skinner JS, Farrer M, Albers CJ, Piper K, Neil HA, Adams PC. Serum Lp(a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery. Heart 1997 Aug;78(2):131-5.
79. Solfrizzi V, Colacicco AM, D'Introno A, et al. All-cause mortality and competing risks of fatal and nonfatal vascular events in the Italian longitudinal study on aging: impact of lipoprotein(a). Rejuvenation Res 2009 Dec;12(6):395-402.
80. Stubbs P, Seed M, Lane D, Collinson P, Kendall F, Noble M. Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes. Eur Heart J 1998 Sep; 19(9):1355-64.
81. Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 2006 Sep 20;296(11):1363-70.
82. Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol 2008 Jul 8;52(2):124-31.
83. Sweetnam PM, Bolton CH, Downs LG, et al. Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly study. Eur J Clin Invest 2000 Nov; 30(11):947-56.
84. Thogersen AM, Soderberg S, Jansson JH, et al. Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction. Eur J Cardiovasc Prev Rehabil 2004 Feb; 11(1):33-40.
85. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation 2007 Apr 24;115(16):2119-27.
86. Wald NJ, Law M, Watt HC, et al. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet 1994 Jan 8;343(8889):75-9.
87. Wang W, Hu D, Lee ET, et al. Lipoprotein(a) in American Indians is low and not independently associated with cardiovascular disease. The Strong Heart Study. Ann Epidemiol 2002 Feb; 12(2):107-14.
88. Wattanakit K, Folsom AR, Chambless LE, Nieto FJ. Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2005 Apr; 149(4):606-12.
89. Woodward M, Rumley A, Welsh P, MacMahon S, Lowe G. A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease. J Thromb Haemost 2007 Sep;5(9):1795-800.
90. Zairis MN, Ambrose JA, Manousakis SJ, et al. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am Coll Cardiol 2002 Oct 16; 40(8):1375-82.
91. Milionis HJ, Winder AF, Mikhailidis DP. Lipoprotein (a) and stroke. J Clin Pathol 2000 Jul;53(7):487-96.
92. Poon M, Zhang X, Dunsky KG, Taubman MB, Harpel PC. Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation 1997 Oct 21;96(8):2514-9.
93. Sotiriou SN, Orlova VV, Al-Fakhri N, et al. Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. Faseb J 2006 Mar;20(3):559-61.
94. Fujisawa M, Haramaki R, Miyazaki H, Imaizumi T, Okuda S. Role of lipoprotein (a) and TGF-beta 1 in atherosclerosis of hemodialysis patients. J Am Soc Nephrol 2000 Oct;11(10): 1889-95.
95. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993 Jun 11; 260(5114):1655-8.
96. Grainger DJ, Metcalfe JC. Transforming growth factor-beta: the key to understanding lipoprotein(a)? Curr Opin Lipidol 1995 Apr;6(2):81-5.
97. Kojima S, Harpel PC, Rifkin DB. Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol 1991 Jun; 113(6):1439-45.
98. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993 Apr 29;362(6423):801-9.
99. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999 Jan 14;340(2):115-26.
100. Cooper JA, Miller GJ, Humphries SE. A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. Atherosclerosis 2005 Jul;181(1): 93-100.
101. von Eckardstein A, Schulte H, Assmann G. Vergleich internationaler Konsens-Empfehlungen zur Erkennung des praesymptomatischen Hochrisikopatienten fuer den Herzinfarkt in Deutschland. Z Kardiol 2005;94:52-60.
102. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel, Evaluation and Treatment of High Blood Cholesterol in Adults. National Institutes of Health, Bethesda 2002.
103. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998 Jul 23;339(4):229-34.
104. Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Type 2 diabetes as a "coronary heart disease equivalent": an 18year prospective population-based study in Finnish subjects. Diabetes Care 2005 Dec;28(12):2901-7.
105. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000 Aug 29;102(9):1014-9.
106. Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998 Jan;21(1):69-75.
107. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Agespecific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 Dec 14;360(9349):1903-13.
108. Teo KK, Ounpuu S, Hawken S, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006 Aug 19;368(9536):647-58.
109. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004 Sep 11-17;364(9438):937-52.
110. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004 Jun26;328(7455):1519.
111. Winkler K, Abletshauser C, Friedrich I, Hoffmann MM, Wieland H, Marz W. Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab 2004 Mar;89(3):1153-9.
112. Marz W, Grutzmacher P, Paul D, Siekmeier R, Schoeppe W, Gross W. Effects of lovastatin (20-80 mg daily) on lipoprotein fractions in patients with severe primary hypercholesterolemia. Int J Clin Pharmacol Ther 1994 Feb;32(2):92-7.
113. Angelin B. Therapy for lowering lipoprotein (a) levels. Curr Opin Lipidol 1997 Dec;8(6):337-41.
114. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004 Jul 13; 110(2):227-39.